Biocryst Pharmaceuticals (BCRX) Profit After Tax Growth (5y) (2015 - 2026)
Biocryst Pharmaceuticals (BCRX) Profit After Tax Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - |
| 10 | Biocryst Pharmaceuticals | 2.47 Bn | 2.12 Bn | 214.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.71% |
| Mar 31, 2026 | -62.21% |
| Dec 31, 2025 | 20.76% |
| Sep 30, 2025 | 17.92% |
| Jun 30, 2025 | 16.34% |
| Mar 31, 2025 | 14.94% |
| Dec 31, 2024 | -102.94% |
| Sep 30, 2024 | 17.89% |
| Jun 30, 2024 | 19.56% |
| Mar 31, 2024 | 55.11% |
| Dec 31, 2023 | -17.61% |
| Sep 30, 2023 | -4.02% |
| Jun 30, 2023 | -32.50% |
| Mar 31, 2023 | -15.65% |
| Dec 31, 2022 | -29.53% |
| Sep 30, 2022 | -22.95% |
| Jun 30, 2022 | -28.37% |
| Mar 31, 2022 | -39.16% |
| Dec 31, 2021 | -31.35% |
| Sep 30, 2021 | -38.51% |